Health Condition 1: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung
Conditions
Interventions
None listed
Sponsors
Kerala Startup Mission
Eligibility
Inclusion criteria
Inclusion criteria: 1. Non small cell carcinoma lung of any histology who have received treatment with immune checkpoint inhibitor therapy between 2017-2021. 2. Patients should have taken regular treatment as per prescribed protocol for at least 3 months or till first radiological response assessment by iRESIST, whichever is later. 3. Drug treatments include Pembrolizumab/Nivolumab/Durvalumab/Atezolizumab either in combination with chemotherapy or as single agents. 4. Stage IV or recurrent disease. 5. Any line of treatment is included 6. Combination with radiation is included 7. Hematoxylin – Eosin slide with/without corresponding FFPE block of tumor biopsy tissue is available. 8. Clinical record of response to ICI therapy is available.
Exclusion criteria
Exclusion criteria: 1. Documented infectious pneumonia during first 3 months of therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome is development of computational model that predicts responders to immune checkpoint inhibitors with 80% sensitivity.Timepoint: Assessment of response will be at 3 months of starting ICI therapy in retrospective cohort. | — |
Secondary
| Measure | Time frame |
|---|---|
| NilTimepoint: NA | — |
Countries
India
Contacts
Public ContactDr Durga Prasan
64 Codon Pvvt. Ltd
Outcome results
None listed